Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 15/100

Termination Rate

0.0%

0 terminated out of 8 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

6Total

Not Applicable (1)

P 1 (3)

P 2 (1)

P 4 (1)

Trial Status

Recruiting5

Completed1

Active Not Recruiting1

Unknown1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT04755205Recruiting

A Natural History Study of Children and Adults With Olfactory Neuroblastoma

NCT06814496Phase 1Recruiting

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

NCT06479811Phase 1Recruiting

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

NCT06607692Phase 1Recruiting

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

NCT04087902Active Not Recruiting

Long-Term Longitudinal QoL in Patients Undergoing EEA

NCT04081701Phase 4Recruiting

68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.

NCT05012098Phase 2Completed

Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON).

NCT01586767Not ApplicableUnknown

Intensity-Modulated or Proton Radiation Therapy for Sinonasal Malignancy

Showing all 8 trials